Cardiosense Appoints Medtech Executive John Martin, MD as EVP and Chief Medical Officer

Veteran medtech leader and renowned vascular surgeon joins Cardiosense to accelerate pivotal clinical and commercial milestones following the company’s recent 510(k) clearance for its CardioTag™ device

CHICAGO--(BUSINESS WIRE)--Cardiosense, a leading medical AI company transforming cardiovascular disease management, today announced the appointment of John Martin, MD, MBA, as Executive Vice President and Chief Medical Officer. Martin, a practicing vascular surgeon and seasoned healthtech executive, will lead the company’s clinical development and product strategy as the company advances through key regulatory milestones and prepares for commercial launch.

“John’s rare combination of clinical expertise and medtech leadership is precisely what Cardiosense needs during this transformative phase,” said Amit Gupta, Cardiosense Co-founder and CEO. “As we complete our validation study for our AI algorithm for cardiac filling pressures and advance towards regulatory submission, John’s leadership will accelerate our mission to expand access to personalized, noninvasive hemodynamic-guided care for the millions living with heart failure and other critical conditions.”

Martin joins Cardiosense with extensive executive leadership experience at Butterfly Network, where he helped lead efforts to bring advanced imaging and monitoring solutions into everyday clinical workflows in the hospital, clinics, emergency departments, remote care venues, and at home. He is a practicing vascular surgeon at the University of Maryland Vascular Center at Annapolis and the founder of the Heart Health Foundation, a nonprofit focused on education, prevention, and early detection of cardiovascular disease. Across clinical, industry, and community settings, Martin has championed patient-centered innovations that improve outcomes while reducing cost and complexity in care delivery.

“Cardiosense is building something truly special at the intersection of AI and medicine. From the operating room to outpatient care, Cardiosense has the potential to transform how we guide therapy, putting actionable, hemodynamic data in the hands of clinicians, and eventually patients, for self-guided care at home,” said Martin. “As a practicing physician, I’ve seen firsthand how urgently we need better tools for managing volume in heart failure, and we have a line-of-sight to provide value for other conditions such as renal disease, trauma and more. We’re at a can’t-miss junction to open the aperture beyond heart failure and redefine how we manage volume across conditions and settings—noninvasively, affordably, and at scale.”

Martin’s appointment follows the recent FDA 510(k) clearance of the CardioTag device, a significant step towards advanced cardiac function monitoring. The company anticipates De Novo classification for its first AI algorithm for noninvasive pulmonary capillary wedge pressure (PCWP) estimation in the coming year. The company recently published results from the SEISMIC-HF I study, the first large-scale study to show that a noninvasive wearable and AI algorithm can estimate PCWP with accuracy on par with implantable sensors, in the Journal of the American College of Cardiology: Heart Failure. A recent editorial review highlights strong model performance across sex, race, BMI, and presence of atrial fibrillation, suggesting the technology could overcome key limitations of implantables, namely procedural risk, patient burden, and low penetration among eligible heart failure populations.

Although proven clinically beneficial, implantable hemodynamic sensors have reached fewer than 1% of eligible patients today. Cardiosense’s noninvasive approach aims to significantly expand patient access to hemodynamic-guided care across heart failure and other volume-sensitive conditions.

For the latest news and information, follow Cardiosense on X and LinkedIn, or visit: www.cardiosense.com.

About Cardiosense

Cardiosense is a leading medical AI company redefining how we detect, monitor, and manage cardiac disease. Built on over a decade of clinical and scientific research, the company is developing novel wearable sensors and machine learning algorithms that translate raw physiological signals into clinically actionable parameters to detect early signs of cardiac disease, guide personalized therapy, and improve patient outcomes.

The CardioTag device has been cleared to market as a class II medical device.

PCWP Analysis Software is an investigational device pending FDA approval.